Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Neuland Laboratories Ltd

Neuland Labs. | 524558

Market Closed
₹20,642.00
₹460.02 (-2.18%)
As on 22/11/26, 1:36 PM
Market Cap27,073.63 CR
Current Price₹20,642
High / Low₹24,225 / 11,500
PE Ratio42.57
Book Value₹1,452.37
Dividend Yield0.28%
ROCE26.45%
ROE21.47%
Face Value₹2.00
Current Vol.37,328
Average Vol.---
ISININE794A01010
PB Ratio8.27
Debt to Equity0.13
Net Profit Margin17.99
Operating Margin29.89

NEULANDLAB - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹21,102₹21,050
₹20,642
Previous CloseToday's Open
₹11,500₹24,225
₹20,642
52W Low52W High
₹21,050Today's Open
₹21,102Previous Close
37,328Volume
₹11,50052W Low
₹24,22552W High

Ratios

No data available

About Company

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao
  • The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin
  • Neuland Drugs & Pharmaceuticals Pvt
  • , a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992
  • NLL manufactures bulk drugs
  • The Company came out with its initial public offering in Apr
  • '94 at a premium of Rs 35 aggregating Rs 5
  • 69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix
  • The cost of the project as estimated by ICICI was Rs 15
  • NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands

Ethics: Neuland Laboratories Ltd is flagged for

paw image

Animal Cruelty

The company engages directly in some form of animal cruelty through its business.

worldwide image

Adequate

The company demonstrates adequate ESG practices with room for improvement.

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI51.09
SMA 2020201.25
SMA 5020929.70
SMA 10020946.16
SMA 20017900.98
SMA 1020864.70
MACD_12_26_Days185.21
EMA10Day20821.85
EMA20Day20567.16
EMA50Day20663.20
MACD_12_26_9_Days188.69
EMA100Day20229.75
EMA200Day18806.06

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth36.98%
ROE21.43%
EBITDA Margin29.89%

All figures in ₹ Crores

Indicators20262025202420232022
Revenue
2,022.99
1,476.84
1,558.58
1,191.20
951.08
Interest
23.95
8.30
14.00
13.07
13.50
Expenses
1,448.49
1,153.58
1,095.99
919.36
808.46
Financing Profit
604.66
343.77
475.13
281.59
144.70
Financing Margin %
30%
23%
30%
24%
15%
Other Income
30.17
20.51
12.54
9.75
2.08
Depreciation
91.74
65.55
59.70
52.78
49.04
Profit before tax
488.98
346.33
401.44
215.75
82.16
Tax %
26%
25%
25%
24%
22%
Net Profit
364.00
260.11
300.08
163.52
63.82
EPS in Rs
283.71
202.74
233.89
127.45
49.74
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

DealDateTypeQuantityPriceTraded %
AIRAVAT CAPITAL TRUST II05 Sept ‘25Purchase8,896₹14,61212.36%
AIRAVAT CAPITAL TRUST05 Sept ‘25Sell8,896₹14,61212.36%

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
04 Aug 2026
AGM
AGM
12 May 2026
24 Jul 2026
Final Dividend (₹34)
Recommended payment of final dividend of Rs. 34/- (340 %) per equity share on a face value of Rs.10 each, for the financial year 2025-26. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 42nd Annual General Meeting (AGM).
12 May 2026
30 Jul 2025
AGM
AGM
15 May 2025
18 Jul 2025
Final Dividend (₹12)
Recommended payment of final dividend of Rs. 12/- (120 %) per equity share on a face value ofRs.10 each, for the financial year 2024-25. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 41st Annual General Meeting (AGM). Pursuant to Regulation 42 of SEBI Listing Regulations the record date for the purpose of determining the shareholders eligible to receive the final dividend for the financial year ended March 31, 2025, has been fixed as July 18, 2025.
15 May 2025
31 Jul 2024
AGM
AGM
10 May 2024
13 Jul 2024
Final Dividend (₹14)
Recommendation of final dividend for the financial year 2023-24
10 May 2024
27 Jul 2023
AGM
AGM
11 May 2023
12 Jul 2023
Final Dividend (₹10)
Outcome of Board Meeting held on May 11, 2023 - Audited Financial Results and recommendation of Final Dividend for financial year 2022-2023
11 May 2023
02 Aug 2022
AGM
AGM
17 Jun 2022
15 Jul 2022
Final Dividend (₹5)
Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2022, inter alia, have recommended payment of final dividend of Rs. 5.00/- (50%) per equity share on a face value of Rs.10 each, subject to the approval of members of the Company.
10 May 2022

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
20,633
26,472
59
13
48
0
17.99%
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 140 Results

Frequently Asked Questions

What is Share Price of Neuland Laboratories Ltd?

The current share price of Neuland Laboratories Ltd (Neuland Labs.) is ₹20642.00. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Neuland Laboratories Ltd?

The Price-to-Earnings (P/E) ratio of Neuland Laboratories Ltd is 59.83. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Neuland Laboratories Ltd?

Neuland Laboratories Ltd has a 52-week high of ₹24225.00 and a 52-week low of ₹11500.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Neuland Laboratories Ltd?

Neuland Laboratories Ltd offers a dividend yield of 0.16%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Neuland Laboratories Ltd?

The Earnings Per Share (EPS) of Neuland Laboratories Ltd is ₹352.73. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Neuland Laboratories Ltd?

Neuland Laboratories Ltd has a Return on Equity (ROE) of 21.47%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2